But it remains to be seen whether drug regulators will go along with a new way of making medicines. To do so, agencies like the U.S. Food and Drug Administration will need to rewrite their rules for validating the safety of medicines. Instead of signing off on the production facility and manufactured drug samples, regulators would have to validate that reactionware produces the desired medication. Cronin agrees it’s a hurdle. But he argues that future printed reactors could simply include a final module containing standard validation tests that produce a visual readout, much like a pregnancy test. “I think it’s manageable.”
Digitized chemistry on demand could also undermine drug counterfeiters.
Comments are closed.